Sangamo Therapeutics (SGMO) Tops Q4 EPS by 4c

Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $27.23 million versus the consensus estimate of $26.86 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Fox upgraded to overweight as Roku deal, ad strength lift outlook
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04